• Johnson & Johnson released first comprehensive Phase 2/3 ENERGY results showing IMAAVY improved anemia in warm autoimmune hemolytic anemia versus placebo.
• Findings will be presented at EHA 2026, positioning the drug as a potential first FDA-approved option in a disease with none.
• Trial showed a rapid onset of benefit with durable responses over the study period, supporting use in patients needing sustained control.
• Patients also reported less fatigue; steroid use trended lower, strengthening the product’s differentiation versus broad immunosuppression.
• Data underpin an sBLA that has received FDA Priority Review, a key near-term regulatory catalyst for the franchise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: NY79625) on June 11, 2026, and is solely responsible for the information contained therein.